BD account plan
Advancing global health solutions
At a glance
BD (Becton, Dickinson and Company) is a US medical technology company with FY2025 revenues of $21.840 billion and about 72,000 associates in 61 countries.
Becton, Dickinson and Company (BD), headquartered in Franklin Lakes, New Jersey, develops, manufactures and sells medical supplies, devices and drug-delivery products to hospitals, clinicians, pharmacies and the pharmaceutical industry. In FY2025 (year to September 30, 2025) revenues were $21.840 billion, up 8.2%, with net income from continuing operations of $1,678 million; it employed about 72,000 associates in 61 countries. On February 9, 2026 BD completed the spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters, receiving a $4 billion cash distribution. The remaining "New BD" reports four segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional.
Business units
Medical Essentials
$1,675 million in Q3 FY2026Medication Delivery Solutions (IV catheters, vascular access, syringes and needles) and Specimen Management (BD Vacutainer blood collection). Q3 FY2026 revenue grew 4.5%, with Vacutainer share gains in the US offset by China volume-based procurement.
Connected Care
$1,224 million in Q3 FY2026Medication Management Solutions (BD Alaris infusion pumps, BD Pyxis dispensing, pharmacy automation) and Advanced Patient Monitoring, the former Edwards Lifesciences Critical Care group. Led by Bilal Muhsin; Advanced Patient Monitoring grew 10.9% in Q3 FY2026 while Alaris faced a tough prior-year comparison.
BioPharma Systems
$670 million in Q3 FY2026Prefillable syringes, safety and self-injection systems sold to pharmaceutical companies. Grew 6.6% in Q3 FY2026 on double-digit biologics growth led by GLP-1 delivery products, partly offset by lower vaccine demand.
Interventional
$1,414 million in Q3 FY2026Peripheral Intervention, Urology and Critical Care (including PureWick) and Surgery (including ChloraPrep infection prevention). Grew 6.4% in Q3 FY2026; Peter Menziuso became President of BD Interventional from June 1.
Strategic priorities
- Excellence Unleashed strategy
- The New BD strategy rests on three priorities: compete (gain share in the fastest-growing areas of medtech), innovate (a more focused pipeline) and deliver (safety, quality, reliable supply and cash flow).
- Commercial investment
- Under its first Chief Revenue Officer, Mike Feld, BD put about $35 million of incremental commercial investment into targeted areas, growing the US APM and PI sales teams by 15% and deploying AI tools to sales reps.
- Growth platforms
- BD is reallocating R&D to connected care, lower-cost care settings and chronic disease; biologic drug delivery, Advanced Patient Monitoring, PureWick and advanced tissue regeneration grew double digits in Q3 FY2026.
- GLP-1 drug delivery
- BioPharma Systems has approximately 100 agreements signed across novel and biosimilar GLP-1 programs, and biologics are about 55% of Pharmaceutical Systems revenue.
- BD Excellence productivity
- The manufacturing network has been cut to around 50 sites, plants deliver approximately 8% gross productivity, and a $200 million cost-out program was at a $150 million run rate in Q2 FY2026.
- Capital allocation
- Buybacks are the top priority while net leverage of approximately 2.9x is brought toward a 2.5x target, with a 90% free cash flow conversion target over time.
Latest results
In Q3 FY2026 (quarter ended June 30, 2026), BD's first full quarter after the Waters transaction, revenues were $4.983 billion, up 5.4% reported and 4.4% FXN; adjusted operating margin was 24.9% and adjusted EPS $3.23. Gross profit margin fell to 46.4% from 47.3% on tariffs, labor costs and El Paso charges. Nine-month operating cash flow rose to $2.104 billion and total debt fell to $16,808 million. FY2026 guidance was raised to revenue growth toward the high end of the low single-digit FXN range, an adjusted operating margin of approximately 25% and adjusted EPS of $12.62 to $12.72. FY2027 is framed as low single-digit revenue growth because of a 200 basis point Alaris headwind.
Investments and deals
- Waters combination
- The Biosciences and Diagnostic Solutions business was spun off and combined with Waters on February 9, 2026; BD shareholders received 39.2% of the combined company and BD used the $4 billion cash distribution for $2 billion of share repurchases and $2 billion of debt repayment.
- Advanced Patient Monitoring acquisition
- Edwards Lifesciences' Critical Care product group was acquired on September 3, 2024 for $3.914 billion.
- AI-enabled products
- Pyxis Pro, the first AI-enabled Pyxis, is launching, and the BD Incada AI platform will connect Alaris, Pyxis and Advanced Patient Monitoring.
- Digital supply chain platform
- BD has begun deploying a standardized digital platform designed to run AI across its end-to-end supply chain.
- Sterilization technology
- BD is investing in new sterilization technology to meet EPA ethylene oxide rules.
Challenges and risks
- FDA quality actions
- The El Paso plant making ChloraPrep and PurPrep received an FDA Warning Letter on April 30, 2026; the Alaris infusion pump consent decree remains in force.
- Tariffs and input costs
- Tariffs cost about 110 basis points of margin in Q3 FY2026, and BD estimated that oil above $100 would mean about a $60 million to $70 million impact on COGS.
- China, vaccines and Alaris
- China volume-based procurement and lower vaccine demand weigh on growth, and the end of Alaris remediation creates a 200 basis points headwind in FY2027.
- Pricing and reimbursement pressure
- GPO and health-system consolidation and CMS's proposed expansion of competitive bidding pressure prices.
- Cybersecurity
- Connected products and legacy IT increase BD's cyber exposure.
What leadership says
“Through BD Excellence, we've built one of the most resilient supply chains in our industry with back orders at record lows and service levels at record highs.”
“we now have approximately 100 agreements signed across novel and biosimilar GLP-1 programs”
“We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. This was our first full quarter operating as New BD.”
Where a supplier can help
- Quality remediation support
- Tied to the El Paso Warning Letter: independent quality assessment, sterility assurance, contamination control and laboratory compliance providers fit BD's commitment to remediate the site.
- Supply chain AI and data
- Tied to the digital supply chain platform investment: software, data integration and analytics vendors can support the AI platform BD is deploying across its supply chain.
- Sales enablement tools
- Tied to the commercial investment priority: CRM, sales compensation and AI sales tools fit BD's change of rep compensation and tooling under its Chief Revenue Officer.
- GLP-1 capacity
- Tied to the GLP-1 drug delivery priority: suppliers of components, automation and manufacturing capacity for prefillable syringes and pens can support the roughly 100 GLP-1 programs.
- Cost and tariff mitigation
- Tied to the tariff and input-cost challenge: sourcing, resin hedging and logistics partners can help BD offset tariff and oil-linked cost increases.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like BD?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year ended September 30, 2025
- BD (Becton, Dickinson and Company) is a global medical technology company selling medical supplies, devices, laboratory equipment and diagnostic products to hospitals, clinicians, labs, life science researchers, the pharmaceutical industry and the public; about 72,000 associates in 61 countries (September 30, 2025).
- FY2025 (year to September 30, 2025) revenues were $21.840 billion, up 8.2% (4.8% from the acquired Advanced Patient Monitoring unit, 3.2% volume/other, -0.3% pricing); United States $12,790 million, International $9,049 million.
- Three segments in FY2025: BD Medical ($11,456 million, segment operating income 36.1% of revenues), BD Life Sciences ($5,167 million, 31.8%) and BD Interventional ($5,217 million, 43.2%).
- Effective October 1, 2025, BD reorganized into five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences; Life Sciences (Biosciences and Diagnostic Solutions) was to be combined with Waters Corporation in a Reverse Morris Trust, with BD shareholders owning about 39.2% of the combined company and BD receiving about $4 billion in cash.
- Strategy anchored on three pillars, "grow, simplify and empower": innovation in smart devices, robotics, analytics and AI, tuck-in acquisitions in faster-growing segments, and the BD Excellence program for productivity and margin.
- Net income from continuing operations $1,678 million, diluted EPS $5.82; operating cash flow $3.430 billion; capex $760 million; dividends $1.196 billion and about $1 billion of share repurchases; total debt $19,181 million.
- Headwinds named by the company: China volume-based procurement (VoBP), lower US government research funding, lower vaccine demand, and tariffs expected to raise FY2026 operating expense.
- Regulatory exposure: the Alaris infusion pump consent decree with the FDA, a November 2024 FDA Warning Letter on the Pyxis dispensing quality system, and ethylene oxide sterilization rules.
- Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (Q3 FY2026)
- Q3 FY2026 (quarter ended June 30, 2026) revenues were $4.983 billion, up 5.4% reported and 4.4% FXN; United States $3,081 million (+6.9%), International $1,902 million (+3.2%, 0.6% FXN).
- First full quarter after the February 9, 2026 spin-off of the Biosciences and Diagnostic Solutions business and its combination with Waters; BD shareholders received 39.2% of the combined company and BD received a $4 billion cash distribution, used for $2 billion of share repurchases and $2 billion of debt repayment.
- Four segments now: Medical Essentials $1,675 million (+4.5%), Connected Care $1,224 million (+4.9%), BioPharma Systems $670 million (+6.6%), Interventional $1,414 million (+6.4%).
- Growth drivers: Advanced Patient Monitoring +10.9% (Acumen IQ Cuff and Sensor), double-digit prefillable biologics led by GLP-1 delivery products, PureWick, Rotarex, BD Vacutainer share gains; headwinds from China VoBP, vaccines and a tough Alaris comparison.
- New strategy "Excellence Unleashed" for "New BD", with three priorities: "compete", "innovate" and "deliver".
- Q3 net income from continuing operations $451 million, diluted EPS $1.64; nine-month operating cash flow $2.104 billion; total debt down to $16,808 million at June 30, 2026.
- On April 30, 2026 the El Paso plant (ChloraPrep, PurPrep) received an FDA Warning Letter; Q3 charges hit Interventional margins. Tariffs and labor costs cut gross margin to 46.4% from 47.3%.
- Restructuring in the first nine months included $450 million of non-cash impairments from exiting activities that no longer fit "Excellence Unleashed".
- BD Q3 fiscal 2026 earnings call transcript
- Tom Polen called Q3 FY2026 "our first full quarter operating as New BD": revenue $5 billion, up 4.4% FXN, adjusted operating margin 24.9%, adjusted EPS $3.23, all ahead of expectations.
- More than 90% of the portfolio grew high single digits; double-digit growth in biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration. Headwinds were concentrated in "less than 10% of our portfolio": the Alaris comparison and vaccines in China.
- FY2026 guidance raised: revenue growth toward the high end of the low-single-digit FXN range, adjusted operating margin about 25%, adjusted EPS $12.62 to $12.72.
- FY2027 framed as low-single-digit revenue growth, with Alaris remediation ending to create a 200 basis point headwind, and "modest leverage" on earnings; then a return to the mid-single-digit algorithm.
- Commercial push under Chief Revenue Officer Mike Feld: about $35 million of targeted sales investment, APM US sales team up about 15%, PI US sales team up 15%; AI tools being put in sales reps' hands.
- BioPharma Systems: approximately 100 agreements across novel and biosimilar GLP-1 programs; a semaglutide launch on the Vystra pen with EMS in Brazil.
- BD Excellence delivers about 8% gross plant productivity, back orders at record lows, over 2,000 Kaizens this year; a standardized digital platform to run AI across the supply chain is being deployed.
- Capital allocation: about $2.3 billion of buybacks year to date, net leverage about 2.9x (target 2.5x), 90% free cash flow conversion target over time; an Investor Day is planned.
- BD Q2 fiscal 2026 earnings call transcript
- On the May 7, 2026 call, Tom Polen named Vitor Roque CFO (interim CFO "since last fall", 25 years at BD) and said the Waters transaction closed "ahead of schedule".
- Q2 FY2026 revenue was $4.7 billion, up 2.6%; adjusted operating margin 24.2%, adjusted EPS $2.90; FY2026 adjusted EPS guidance raised to $12.52 to $12.72.
- Growth platforms (biologic drug delivery, Advanced Patient Monitoring, PureWick, Advanced Tissue Regeneration) grew double digits; Alaris, vaccines and China, under 10% of revenue, weighed.
- BD Excellence: manufacturing network cut roughly in half to about 50 sites, about 8% productivity, $150 million run rate of a $200 million cost-out program; applied to R&D, cutting time to launch by over 10 months on five programs.
- El Paso FDA Warning Letter: ChloraPrep and PurPrep placed on a voluntary US ship hold for about 3 weeks of extra release testing; "no patient safety signals".
- Capital allocation now puts share buybacks first, as BD views its stock as "substantially undervalued", ahead of focused tuck-in M&A; $2 billion repurchased in the quarter and $2.1 billion of debt retired.
- Connected Care: Pyxis Pro, "the first AI-enabled Pyxis", with 75% of wins from competitive conversions; the BD Incada AI platform will connect Alaris, Pyxis and APM.
- GLP-1: two new next-generation GLP-1 deals with large pharma, over 80 biosimilar GLP-1 deals; biologics now about 55% of Pharmaceutical Systems revenue.
Questions about BD
What does BD do?
BD develops, manufactures and sells medical supplies, devices and drug-delivery systems, including IV catheters, BD Vacutainer blood collection, BD Alaris infusion pumps, BD Pyxis dispensing, prefillable syringes and interventional products, to hospitals, pharmacies and pharmaceutical companies.
What is BD's revenue?
FY2025 revenues were $21.840 billion, up 8.2%. In Q3 FY2026, after the Waters transaction, quarterly revenues were $4.983 billion.
How many employees does BD have?
BD employed approximately 72,000 associates in 61 countries as of September 30, 2025.
Who leads BD?
Thomas E. Polen is Chairman, Chief Executive Officer and President; Vitor Roque is Executive Vice President and CFO.
What is BD's strategy?
Under "Excellence Unleashed", BD aims to compete, innovate and deliver: gain share in fast-growing medtech areas, focus its pipeline on connected care and chronic disease, and use BD Excellence for supply and margin.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)